105 research outputs found
Diagnosis and monitoring of hepatitis virus infection in liver transplant patients
No abstract availabl
526 Liver stiffness measured by transient elastography. The influence of biochemical activity
Monitoring liver elasticity: a new tool to measure liver fibrosis during therapy
La fibrosi epatica e’ il maggior indicatore dell’evolutivita’ dell’epatopatia cronica. Tuttavia l’esame istologico, gold standard per definire l’entita’ della fibrosi epatica, richiede l’esecuzione della biopsia epatica che e’ una procedura invasiva e pertanto difficilmente uitilizzabile per monitorare la progressione dell’epatopatia. Scopo dello studio e’ stato valutare l’accuratezza diagnostica dell’elasticita’ epatica misurata con Fibroscan, metodica non invasiva per la valutazione della fibrosi epatica in una coorte di pazienti con epatite cronica virale (HBV e HCV). I risultati hanno dimostrato che l’elasticita’ epatica misurata con Fibroscan correlano significativamente con la fibrosi istologica. Inoltre bassi valori di rigidita’ epatica nei pazienti con remissione biochimica rendono il Fibroscan uitilizzabile per monitorare la terapia antiviral
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases
Liver stiffness, a non-invasive marker of liver disease in the HBV carrier
AIM: To investigate the usefulness of transient elastography by Fibroscan (FS), a
rapid non-invasive technique to evaluate liver fibrosis, in the management of
chronic hepatitis B virus (HBV) carriers.
METHODS: In 297 consecutive HBV carriers, we studied the correlation between
liver stiffness (LS), stage of liver disease and other factors potentially
influencing FS measurements. In 87 chronic hepatitis B (CHB) patients, we
monitored the FS variations according to the spontaneous or treatment-induced
variations of biochemical activity during follow-up.
RESULTS: FS values were 12.3 +/- 3.3 kPa in acute hepatitis, 10.3 +/- 8.8 kPa in
chronic hepatitis, 4.3 +/- 1.0 kPa in inactive carriers and 4.6 +/- 1.2 kPa in
blood donors. We identified the cut-offs of 7.5 and 11.8 kPa for the diagnosis of
fibrosis >or= S3 and cirrhosis respectively, showing 93.9% and 86.5% sensitivity,
88.5% and 96.3% specificity, 76.7% and 86.7% positive predictive value (PPV),
97.3% and 96.3% negative predictive value (NPV) and 90.1% and 94.2% diagnostic
accuracy. At multivariate analysis in 171 untreated carriers, fibrosis stage (t =
13.187, P < 0.001), active vs inactive HBV infection (t = 6.437, P < 0.001),
alanine aminotransferase (ALT) (t = 4.740, P < 0.001) and HBV-DNA levels (t =
or-2.046, P = 0.042) were independently associated with FS. Necroinflammation
score (t = 2.158, > 10/18 vs <or= 10/18, P = 0.035) and ALT levels (t = 3.566, P
= 0.001) were independently associated with LS in 83 untreated patients without
cirrhosis and long-term biochemical remission (t = 4.662, P < 0.001) in 80
treated patients. During FS monitoring (mean follow-up 19.9 +/- 7.1 mo) FS values
paralleled those of ALT in patients with hepatitis exacerbation (with 1.2 to
4.4-fold increases in CHB patients) and showed a progressive decrease during
antiviral therapy.
CONCLUSION: FS is a non-invasive tool to monitor liver disease in chronic HBV
carriers, provided that the pattern of biochemical activity is taken into
account. In the inactive carrier, it identifies non-HBV-related causes of liver
damage and transient reactivations. In CHB patients, it may warrant a more
appropriate timing of control liver biopsies
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases
Liver stiffness was measured by transient elastography (FibroScan) in 228
consecutive patients with chronic viral hepatitis, with (115) or without
cirrhosis (113), to study its correlations with serum transaminases [alanine
aminotransferase (ALT)], fibrosis stage and surrogate noninvasive markers of
fibrosis (APRI, FORNS, FibroTest and hyaluronic acid). The dynamic profiles of
serum transaminases and liver stiffness were compared by multiple testing in 31
patients during a 6-month follow-up. We identified 8.3 and 14 kPa as the fibrosis
>/=F2 and cirrhosis cut-offs, respectively: their sensitivities were 85.2%/78.3%;
specificities 90.7%/98.2%; positive predictive values 93.9%/97.8%; negative
predictive values 78.8%/81.6%; diagnostic accuracies 87.3%/88.2%. FibroScan
performed better than the other surrogate markers of fibrosis (P < 0.001). Other
than fibrosis, other factors independently associated with liver stiffness were
ALT for all patients and chronic hepatitis patients (P < 0.001), and 12-month
persistently normal ALT (biochemical remission, P < 0.001) in cirrhotics. In
patients with biochemical remission either spontaneous or after antiviral therapy
(48 of 228, 21%), liver stiffness was lower than in patients with identical
fibrosis stage, but elevated ALT (P < 0.001). The liver stiffness dynamic
profiles paralleled those of ALT, increasing 1.3- to 3-fold during ALT flares in
10 patients with hepatitis exacerbations. Liver stiffness remained unchanged in
21 with stable biochemical activity (P = 0.001). In conclusion, transient
elastography is a new liver parameter that behaves as a reliable surrogate marker
of fibrosis in chronic viral hepatitis patients, provided that its relationship
with major changes of biochemical activity is taken into account
- …